🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Surveillance, Assessment and Detection of Influenza Associated Respiratory Infections in HIV Positive and Negative Individual in Lusaka, Zambia.

Recruitingn/aAges 18 Years - anyAllCentre for Infectious Disease Research in Zambia
NCT07030075 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background and rationale:The World Health Organisation (WHO), estimates influenza global deaths at 290,000 to 650,000 annually. Although influenza is mostly associated with upper respiratory tract infections (URTIs), its role in lower respiratory tract infections (LRTIs) and the associated poor clinical outcomes have been overlooked in sub-Saharan Africa. A study conducted in eight SSA countries estimated that 8.2% of cases and 2.8% of deaths from LRTIs were due to primary infection with influenza. Pneumonia and influenza-associated illness are responsible for 8.5% of respiratory deaths in Zambia. However, in routine practice, testing to distinguish between bacterial and viral etiology of RTIs is seldom done outside sentinel surveillance due to the high cost and lack of available testing options. This consequently underestimates viral RTIs in the population. It is particularly important

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * age ≥18 years old * presenting with flu-like symptoms or acute respiratory infection with ≥2 to 7 days history of cough and /or sore throat and fever, +/- sneezing, +/- congestion, +/- myalgia, +/- fatigue, +/- wheezing, shortness of breath)\[55-57\] * willing to share their HIV status or be tested * willing to share their COVID-19 vaccination status * able and willing to give informed consent * willing to provide a nasal/ nasopharyngeal sample for testing as part of standard of care * willing to provide exhaled breath aerosol samples i.e. wear a mask and provide a breath sample * willing to fill a symptoms diary card for symptom tracking for 7 days * agree to be followed-up and attend study visits up to two weeks after study entry Exclusion Criteria: * individuals who are unwilling to provide any reference standard samples such as the nasopharyngeal swabs * those with symptoms for \>7 days, or * those unwilling or unable to provide informed consent
💊

What it tests

  • Not listed
📍

Where

2 sites
Chawama 1st level Hospital
Lusaka, Zambia
Kanyama 1st Level Hospital
Lusaka, Zambia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy